| Mar 26 | Mar 25 | Mar 24 | Mar 23 | Mar 22 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 1.07M | $ 1.74M | $ 1.93M | $ 1.97M | $ 2.60M |
| Gross Profit | $ 183.28K | $ 367.43K | $ 553.97K | $ 426.27K | $ 1.25M |
| Operating Income | $ -7.12M | $ -2.68M | $ -2.52M | $ -5.61M | $ -5.19M |
| EBITDA | $ -6.98M | $ -2.57M | $ -2.35M | $ -5.21M | $ -5.05M |
| Net Income | $ -6.21M | $ -3.30M | $ -3.10M | $ -5.93M | $ -5.74M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 28.18M | $ 18.10M | $ 12.07M | $ 17.37M | $ 15.52M |
| Total Assets | $ 34.75M | $ 21.66M | $ 23.13M | $ 29.55M | $ 33.55M |
| Total Debt | $ 1.12M | $ 983.88K | $ 2.65M | $ 3.76M | $ 10.74M |
| Net Debt | $ -27.06M | $ -17.12M | $ -9.42M | $ -13.61M | $ -4.78M |
| Total Liabilities | $ 5.05M | $ 6.22M | $ 9.20M | $ 14.86M | $ 17.12M |
| Stockholders' Equity | $ 29.71M | $ 15.44M | $ 13.93M | $ 14.69M | $ 16.42M |
| Cash Flow | |||||
| Free Cash Flow | $ -4.02M | $ -2.35M | $ -1.94M | $ -151.44K | $ -2.44M |
| Operating Cash Flow | $ -4.02M | $ -2.35M | $ -1.93M | $ -80.76K | $ -2.37M |
| Investing Cash Flow | $ -1.25M | $ 63.52K | $ 26.42K | $ -12.30K | $ -46.91K |
| Financing Cash Flow | $ 14.43M | $ 8.40M | $ -2.62M | $ 2.94M | $ 1.63M |
China SXT Pharmaceuticals Forecast EPS vs Actual EPS
Currently, no data available
Please return soon. This page is being updated.